Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-14

Clinical Trial Update: A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Lu AG09222 in combination with ubrogepant for migraine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lu AG09222
  • Ubrogepant (ubrogepant)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Migraine | Phase 1 | Status: COMPLETED